OTCM
UNVC
Market cap5mUSD
Jul 11, Last price
0.00USD
1D
-3.10%
1Q
-18.03%
Name
Univec Inc
Chart & Performance
Profile
Univec, Inc., through its subsidiaries, produces, licenses, and markets medical products in the United States and internationally. It primarily provides auto-disable and safety syringes. The company offers 1 cc AD-syringe for aspirating and non-aspirating applications, which are used for dispensing dosages of allergy, immunization, and insulin medicines. It also manufactures and markets sliding sheath syringes that are designed to protect patients and healthcare workers from needle stick injuries; and bifurcated needle safety syringes, which are used in administering smallpox vaccines in response to bio-terrorist threats. Univec markets its auto-disable syringes and sliding sheath safety syringes to private hospitals, health facilities, and distributors in the United States, as well as to governments of developing countries. In addition, it assists pharmaceutical companies in marketing, fulfillment, and tracking drug samples via an online system connecting pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
Income | |||||
Revenues | 21 -36.55% | 33 -38.22% | |||
Cost of revenue | 26 | 37 | |||
Unusual Expense (Income) | |||||
NOPBT | (4) | (4) | |||
NOPBT Margin | |||||
Operating Taxes | (2) | 2 | |||
Tax Rate | |||||
NOPAT | (4) | (4) | |||
Net income | (2,597) -2.59% | (2,666) 99.00% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,740 | ||||
BB yield | |||||
Debt | |||||
Debt current | 18 | 13 | |||
Long-term debt | 1,172 | 1,122 | |||
Deferred revenue | |||||
Other long-term liabilities | (1) | ||||
Net debt | 1,190 | 1,135 | |||
Cash flow | |||||
Cash from operating activities | (55) | (1,770) | |||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | 55 | 1,770 | |||
FCF | 1,201 | 894 | |||
Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | (32,400) | (29,803) | |||
Invested Capital | 18,518 | 18,463 | |||
ROIC | |||||
ROCE | 0.03% | 0.03% | |||
EV | |||||
Common stock shares outstanding | 2,523,097 | 2,523,097 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | 1 | 2 | |||
EV/EBITDA | |||||
Interest | 22 | 13 | |||
Interest/NOPBT |